Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Leap Therapeutics, Inc. (LPTX : NSDQ)

• Company Description    Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. Number of Employees: 52

• Price / Volume Information    Yesterday's Closing Price: $0.36 Daily Weekly Monthly 20 Day Moving Average: 3,242,355 shares Shares Outstanding: 41.44 (millions) Market Capitalization: $14.72 (millions) Beta: -0.28 52 Week High: $4.79 52 Week Low: $0.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.87% -19.02% 12 Week -2.26% -17.78% Year To Date -87.64% -88.43%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 47 THORNDIKE STREET SUITE B1-1 - CAMBRIDGE,MA 02141 USA ph: 617-714-0360 fax: - ir@leaptx.com http://www.leaptx.com

• General Corporate Information    Officers Douglas E. Onsi - Chief Executive Officer; President and Chief Finan Christopher K. Mirabelli - Chairman James Cavanaugh - Director Thomas Dietz - Director William Li - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 52187K200 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 41.44 Most Recent Split Date: 6.00 (0.10:1) Beta: -0.28 Market Capitalization: $14.72 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.11 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.71 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 27.45% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -162.15 12/31/24 - -137.05 ROA 06/30/25 - - 03/31/25 - -120.05 12/31/24 - -106.57 Current Ratio 06/30/25 - - 03/31/25 - 2.41 12/31/24 - 3.41 Quick Ratio 06/30/25 - - 03/31/25 - 2.41 12/31/24 - 3.41 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.50 12/31/24 - 0.91 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©